The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2024 | The co-administration of bispecific antibodies and CAR T-cells in CLL: an in vivo study
Martina Seiffert, PhD, German Cancer Research Center, Heidelberg, Germany, discusses a study investigating the co-administration of CD20-bispecific antibodies and CD19 CAR T-cells in chronic lymphocytic leukemia (CLL). Dr Seiffert emphasizes the potential of using bispecific antibodies to stimulate endogenous T-cells, which may enhance the expansion and persistence of CAR T-cells, ultimately improving outcomes in patients. This interview took place at the 2024 European Research Initiative on CLL (ERIC) Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie, GenMab
